scholarly journals P10.07 Mapping the integration sites e1-e2 of hpv-16 andhpv-18 as a tool to evaluate different stages of cervical disease progression

2015 ◽  
Vol 91 (Suppl 2) ◽  
pp. A167.2-A167
Author(s):  
FN Carestiato ◽  
SM Amaro-Filho ◽  
MA Moreira ◽  
RH Barbosa ◽  
YL Furtado ◽  
...  
Keyword(s):  
Disease Progression ◽  
Hpv 16 ◽  
Cervical Disease ◽  
Integration Sites

scholarly journals Association of serum and mucosal neutralizing antibodies to human papillomavirus type 16 (HPV-16) with HPV-16 infection and cervical disease

2008 ◽  
Vol 89 (4) ◽  
pp. 910-914 ◽  
Author(s):  
Zizipho Z. A. Mbulawa ◽  
Anna-Lise Williamson ◽  
Debbie Stewart ◽  
Jo-Ann S. Passmore ◽  
Lynette Denny ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Neutralizing Antibodies ◽  
Antibody Responses ◽  
Normal Cytology ◽  
Hpv 16 ◽  
Human Papillomavirus Type 16 ◽  
Immunodeficiency Virus ◽  
Cervical Disease ◽  
Hpv Types

We investigated neutralizing antibodies to human papillomavirus type 16 (HPV-16) in serum and cervical washes from 84 women with normal cytology or cervical disease. Serum neutralizing antibodies were detected in 78 % of women infected at the cervix with HPV-16, compared with 35 % (P=0.002) of women infected with HPV-16-related types (α9 HPV types), 14 % (P<0.0001) of women infected with HPV-16 non-related types and none of HPV-uninfected women. A significant correlation between HPV-16 infection and serum HPV-16-neutralizing antibodies was observed (r s=0.97; P=0.032). Cervical neutralizing antibodies were detected in 38 % of women with HPV-16 infection and in 17 % of women infected with the HPV-16-related type HPV-31. Cervical neutralizing antibodies correlated with HPV-16 infection (r s=0.95; P=0.08), but not with cervical disease. Serum and cervical HPV-16 antibody responses were not affected significantly by human immunodeficiency virus type 1 infection. In conclusion, serum and cervical HPV-16-neutralizing antibodies were found to correlate with HPV-16 infection, but not with cervical disease.

scholarly journals Features of Pap smears in women of reproductive life with papillomavirus 16, 18

2021 ◽  
pp. 96-97
Author(s):  
Shafag Eldar Aliyeva ◽  
Keyword(s):  
Cervical Cancer ◽  
Epithelial Cells ◽  
Pap Smear ◽  
Reproductive Age ◽  
Pap Smears ◽  
Pathological Changes ◽  
Women Of Reproductive Age ◽  
Hpv 16 ◽  
Sexually Transmitted ◽  
Cervical Disease

Introduction. According to modern data, cervical diseases do not occur by chance. Precancerous lesions vary from person to person and become invasive over time. The need for specific diagnostic methods for early detection of cervical cancer in women of reproductive age always remains relevant. Over the years, numerous diagnostic, cytological and histological studies have been carried out to identify malignant lesions of the cervix. Human papillomavirus (HPV) is a widespread sexually transmitted infection that affects both women and men around the world and plays an important role in the development of cervical disease. It is the most common sexually transmitted virus in the United States of America. For the first time in 1942, Papanicolaou emphasized the possibility of using smears (PAP smears) from the cervix and from the vagina to diagnose cervical disease. PAP preparations of smears are mainly multilayered flat epithelial cells of the ectocervix and vagina, endocervical cylindrical cells, including mononuclear and polynuclear inflammatory cells that enter the vagina through diapedesis from the surface of the epithelial layer, mixing with the mucoid fluid produced by the endocervical epithelial fluid. Purpose — using objective criteria for cytological examination to identify neoplastic changes in the cervix. Materials and methods. The study included 100 women of reproductive age (18–45 years old) during 2015–2020. Of these, 20 were in the control group (group I — control) and 80 — in the high-risk group for cervical cancer (group II — the main group). Group II women were also divided into 2 subgroups: II A — with pathology of the cervix (n=41), II B — without pathology of the cervix (n=39). The study included patients with a positive result on HPV 16/18 including patients whose PAP smears revealed intracellular damage. Pap smears were included in the study according to the following criteria. The smears contained a sufficient number of squamous epithelial cells and their integrity was preserved. Endocervical cells were monitored in all PAP smears. The examination was carried out with at least 5 cells in each, not completely, and with 2 clusters of endocervical glandular or squamous metaplastic cells. Squamous epithelial cells covered at least 10% of the preparation. Bloody, technically artifactic preparations without clinical data have not been studied. The deficit rate did not exceed 3%, and high interest rates on artifacts were not included in the study. Despite the small number of cells in the presence of abnormal cells, this was unequivocally considered sufficient. Results. Interpretation of PAP smear results identified n=35 ASCUS patients, n=24 LSIL, n=21 HSIL patients in the PAP smear positive reproductive age group. HPV serotypes 16.18 were found in 24 of these patients. In women of the II B subgroup, no pathological changes in the cervix were observed. Conclusions. In women of reproductive age with positive HPV 16, 18, for the diagnosis of precancerous diseases of the cervix, taking pap smears is an integral part of the study. As a result of the study, it was revealed that, despite the absence of a clinical picture, pathological changes at the cell level are detected. Key words: HPV16, 18, ASCUS, LSIL, HSIL, PAP.

Polymorphism in the E6 gene of human papillomavirus type 16 in the cervical tissues of Korean women

2005 ◽  
Vol 15 (1) ◽  
pp. 107-112 ◽  
Author(s):  
S. Kang ◽  
Y. T. Jeon ◽  
J. W. Kim ◽  
N. H. Park ◽  
Y. S. Song ◽  
...  
Keyword(s):  
Intraepithelial Neoplasia ◽  
Sequence Variants ◽  
Korean Women ◽  
Nested Polymerase Chain Reaction ◽  
Hpv 16 ◽  
Human Papillomavirus Type 16 ◽  
E6 Gene ◽  
Increased Risk ◽  
Cervical Disease ◽  
Cervical Cancer Development

The aim of this study was to identify sequence variants in the HPV 16 E6 gene in Korean women and to examine the possible association between these sequence variants and cervical cancer development. We examined the HPV 16 DNA of 215 patients with no cervical disease (NCD) (n = 105) or with cervical neoplasia (n = 110) [cervical intraepithelial neoplasia (CIN), n = 61; invasive cervical carcinoma (ICC), n = 49] using the nested polymerase chain reaction (PCR) and PCR-directed sequencing methods. Fifty-four (NCD, n = 10; CIN, n = 17; ICC, n = 27) of the 215 samples contained HPV 16 E6 DNA, but only two (7.4%) of 27 ICC samples had prototype sequences. The most frequently found variation was D25E (in NCD, n = 8, 80%; in CIN, n = 9, 52.9%; in ICC, n = 23, 85.2%). This is a rare variation in western countries. No significance difference was found between the frequencies of D25E variation in cancerous and non-cancerous lesions. Among the 11 kinds of variants identified, four variants were novel and have been registered with GenBank. This study demonstrates that the D25 variant is the most prevalent E6 genomic variant type in Korean population. However, it was not found to be associated with an increased risk of ICC.

Potential coverage of circulating HPV types by current and developing vaccines in a group of women in Bosnia and Herzegovina with abnormal Pap smears

2015 ◽  
Vol 143 (12) ◽  
pp. 2604-2612
Author(s):  
I. SALIMOVIĆ-BEŠIĆ ◽  
M. HUKIĆ
Keyword(s):  
High Risk ◽  
Bosnia And Herzegovina ◽  
Pap Smear ◽  
Multiple Infections ◽  
Pap Smears ◽  
Abnormal Cytology ◽  
Hpv 16 ◽  
Hpv Dna ◽  
Cervical Disease ◽  
Hpv 18

SUMMARYThe objectives of this study were to identify human papillomavirus (HPV) genotypes in a group of Bosnian-Herzegovinian women with abnormal cytology and to assess their potential coverage by vaccines. HPVs were identified by multiplex real-time PCR test (HPV High Risk Typing Real-TM; Sacace Biotechnologies, Italy) of 105 women with an abnormal cervical Pap smear and positive high-risk (HR) HPV DNA screening test. The most common genotypes in the study were HPV-16 (32·6%, 48/147), HPV-31 (14·3%, 21/147), HPV-51 (9·5%, 14/147) and HPV-18 (7·5%, 11/147). The overall frequency of HR HPV-16 and/or HPV-18, covered by currently available vaccines [Gardasil® (Merck & Co., USA) and Cervarix®; (GlaxoSmithKline, UK)] was lower than the overall frequency of other HPVs detected in the study (40·1%, 59/174,P= 0·017). Group prevalence of HR HPVs targeted by a nine-valent vaccine in development (code-named V503) was higher than total frequency of other HPVs detected (68·0%, 100/147,P< 0·001). Development of cervical cytological abnormalities was independent of the presence of multiple infections (χ2= 0·598,P= 0·741). Compared to other HPVs, dependence of cervical diagnosis and HPV-16, -18 (P= 0·008) and HPV-16, -18, -31 (P= 0·008) infections were observed. Vaccines targeting HR HPV-16, -18 and -31 might be an important tool in the prevention of cervical disease in Bosnia and Herzegovina.

scholarly journals Analysis of genetic copy number changes in cervical disease progression

BMC Cancer ◽  
2010 ◽  
Vol 10 (1) ◽  
Author(s):  
Frank A Policht ◽  
Minghao Song ◽  
Svetlana Sitailo ◽  
Anna O'Hare ◽  
Raheela Ashfaq ◽  
...  
Keyword(s):  
Disease Progression ◽  
Copy Number ◽  
Cervical Disease ◽  
Copy Number Changes

scholarly journals HPV Catch-up Vaccination is Effective but Cervical Screening Should Continue

2021 ◽  
Vol 5 (2) ◽  
pp. 51-53
Author(s):  
Nick F. Hallam
Keyword(s):  
High Risk ◽  
Cervical Screening ◽  
Hpv Vaccination ◽  
Herd Immunity ◽  
High Grade ◽  
Human Papillomavirus Vaccination ◽  
Hpv 16 ◽  
Bivalent Vaccine ◽  
Cervical Disease ◽  
Catch Up

This short communication reports additional research that extends the previously published article - Commentary: HPV Catch-Up Vaccination Reduces the Prevalence of HPV 16 and 18 Infections and Cervical Disease: A Retrospective Study.1 One limitation of that study was uncertainty as to whether the catch-up cohort had actually received HPV (human papillomavirus) vaccination. That information has now been obtained. 87 (59%) of the 147 patients in the catch-up cohort had received at least one dose of HPV bivalent vaccine. 69 of these (representing 79% of those vaccinated) had received three doses (as recommended at the time). Both the vaccinated and unvaccinated subsets of the catch-up cohort show a significant reduction in the prevalence of HPV 16 and/or 18 (with/without other high-risk types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) and of high grade cervical disease compared to an earlier unvaccinated cohort. These results confirm the efficacy of HPV catch-up vaccination and the existence of herd immunity following the introduction of national HPV vaccination campaigns. However, 34 patients (23%) in the catch-up cohort had high grade disease (cervical intraepithelial neoplasia [CIN] 2 or worse), 16 of whom had been vaccinated (12 with three doses, one with two doses and three with one dose of HPV bivalent vaccine) and four of those vaccinated had HPV 16 and/or 18 (with/without other high-risk types), the rest had other HPV high risk types. This emphasises the importance of maintaining cervical screening alongside HPV vaccination.

scholarly journals Enhanced disease progression due to persistent HPV-16/58 infections in Korean women: a systematic review and the Korea HPV cohort study

2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Jaehyun Seong ◽  
Sangmi Ryou ◽  
JeongGyu Lee ◽  
Myeongsu Yoo ◽  
Sooyoung Hur ◽  
...  
Keyword(s):  
Cohort Study ◽  
Disease Progression ◽  
Hpv Infection ◽  
High Grade ◽  
Squamous Intraepithelial Lesions ◽  
Hpv 16 ◽  
Persistent Infections ◽  
Hpv Prevalence ◽  
Risk Of Disease ◽  
Intraepithelial Lesions

Abstract Background Persistent human papillomavirus (HPV) infection is a key factor for the development and progression of cervical cancer. We sought to identify the type-specific HPV prevalence by cervical cytology and assess disease progression risk based on high-risk persistent HPV infection in South Korea. Methods To investigate the HPV prevalence by Pap results, we searched seven literature databases without any language or date restrictions until July 17, 2019. To estimate the risk of disease progression by HPV type, we used the Korea HPV Cohort study data. The search included the terms “HPV” and “Genotype” and “Korea.” Studies on Korean women, type-specific HPV distribution by cytological findings, and detailed methodological description of the detection assay were included. We assessed the risk of disease progression according to the high-risk HPV type related to the nonavalent vaccine and associated persistent infections in 686 HPV-positive women with atypical squamous cells of uncertain significance or low-grade squamous intraepithelial lesions from the Korea HPV Cohort Study. Type-specific HPV prevalence was the proportion of women positive for a specific HPV genotype among all HPV-positive women tested for that genotype in the systematic review. Results We included 23 studies in our review. HPV-16 was the most prevalent, followed by HPV-58, -53, -70, -18, and -68. In women with high-grade squamous intraepithelial lesions, including cancer, HPV-16, -18, and -58 were the most prevalent. In the longitudinal cohort study, the adjusted hazard ratio of disease progression from atypical squamous cells of uncertain significance to high-grade squamous intraepithelial lesions was significantly higher among those with persistent HPV-58 (increase in risk: 3.54–5.84) and HPV-16 (2.64–5.04) infections. Conclusions While HPV-16 was the most prevalent, persistent infections of HPV-16/58 increased the risk of disease progression to high-grade squamous intraepithelial lesions. Therefore, persistent infections of HPV-16 and -58 are critical risk factors for cervical disease progression in Korea. Our results suggest that equal attention should be paid to HPV-58 and -16 infections and provide important evidence to assist in planning the National Immunization Program in Korea.

scholarly journals Human Papillomavirus E6E7 mRNA and TERC lncRNA in Situ Detection in Cervical Scraped Cells and Cervical Disease Progression Assessment

2021 ◽  
Author(s):  
Hui Zhao ◽  
Yue He ◽  
Bei Fan ◽  
Yan Wang ◽  
Yu-Mei Wu
Keyword(s):  
Human Papillomavirus ◽  
High Risk ◽  
Disease Progression ◽  
Cervical Cell ◽  
Human Papillomavirus Infection ◽  
Papillomavirus Infection ◽  
Cervical Disease ◽  
Cervical Cells ◽  
Cell Malignancy

Abstract BackgroundHuman papillomavirus screen in female cervical cells has demonstrated values in clinical diagnosis of precancerous lesions and cervical cancers. Human papillomavirus tests of cervical cells by utilizing Polymerase Chain Reaction (PCR) method provides human papillomavirus infection status however no further virus in situ information. Although it is well known that the tests of human papillomavirus E6/E7 RNA location in infected cervical cells and cell internal malignancy molecular will provide clues for gynecologists to evaluate disease progression, there are technique difficulties to preserve RNAs in cervical scraped cells for in situ hybridization. MethodsIn current study, after developing a cervical cell collection and preparation methods for RNA in situ hybridization, we captured the chance to screen 98 patient cervical cell samples and detected human papillomavirus E6/E7 mRNAs of high-risk subtypes, low-risk subtypes and lncRNA TERC in the cells. ResultsThere are 70% consistence between human papillomavirus PCR and human papillomavirus RNA in situ hybridization results in cervical collected cells. Viral E6/E7 mRNAs were observed to distribute in cervical cell nuclear and cytoplasm. Moreover, viral gathered clusters were observed outside of cells through human papillomavirus RNA in situ hybridization. Varied numbers of human papillomavirus infective cells were detected by RNAscope assay in different patients even though they are all human papillomavirus high-risk subtype positive discovered by human papillomavirus PCR results. A cell malignancy related long non-coding RNA, TERC, has been detected in seven patient samples. The patient follow-up information was further analyzed with RNAscope results which indicated a combination of RNAscope positive signals of TERC and human papillomavirus high risk signals in more than 10 cells (cytoplasm or nucleus) may connect with cervical lesion fast progression which deserves further studies in the future.ConclusionsTaken together, current study has provided an observable clue for gynecologists to evaluate human papillomavirus infection stage and cell malignancy status which may contribute for assessment of cervical disease progression.

Sign in / Sign up

Export Citation Format

Share Document